The LKB1 tumor suppressor negatively regulates mTOR signaling

Cancer Cell

Volumn 6, Issue 1, 2004, Pages 91-99

  Shaw, Reuben J ^a,b   Bardeesy, Nabeel ^a,c   Manning, Brendan D ^a,b   Lopez, Lyle ^a,c   Kosmatka, Monica ^a,b   DePinho, Ronald A ^a,c   Cantley, Lewis C ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TARGET OF RAPAMYCIN KINASE; TUBERIN;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CELL CULTURE; CONTROLLED STUDY; GASTROINTESTINAL POLYPOSIS; GENE MUTATION; GERM LINE GENE THERAPY; MOUSE; NONHUMAN; PEUTZ JEGHERS SYNDROME; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANIMALIA; NEXUS;

EID: 3142594193     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2004.06.007     Document Type: Article

References (61)

1. Baas A.F., Kuipers J., van der Wel N.N., Batlle E., Koerten H.K., Peters P.J., Clevers H.C. Complete polarization of single intestinal epithelial cells upon activation of LKB1 by STRAD. Cell. 116:2004;457-466
2. Bardeesy N., Sinha M., Hezel A.F., Signoretti S., Hathaway N.A., Sharpless N.E., Loda M., Carrasco D.R., DePinho R.A. Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature. 419:2002;162-167
3. Boudeau J., Sapkota G., Alessi D.R. LKB1, a protein kinase regulating cell proliferation and polarity. FEBS Lett. 546:2003;159-165
4. Brugarolas J.B., Vazquez F., Reddy A., Sellers W.R., Kaelin W.G. Jr. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell. 4:2003;147-158
5. Cantley L.C., Neel B.G. New insights into tumor suppression. PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway Proc. Natl. Acad. Sci. USA. 96:1999;4240-4245
6. Carretero J., Medina P.P., Pio R., Montuenga L.M., Sanchez-Cespedes M. Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene. Oncogene. 13:2004;4037-4040
7. Cheng S.W., Fryer L.G., Carling D., Shepherd P.R. Thr2446 is a novel mammalian target of rapamycin (mTOR) phosphorylation site regulated by nutrient status. J. Biol. Chem. 279:2004;15719-15722
8. Crute B.E., Seefeld K., Gamble J., Kemp B.E., Witters L.A. Functional domains of the α1 catalytic subunit of the AMP-activated protein kinase. J. Biol. Chem. 273:1998;35347-35354
9. Dennis P.B., Jaeshke A., Saitoh M., Fowler B., Kozma S.C., Thomas G. Mammalian TOR. A homeostatic ATP sensor Science. 294:2001;1102-1105
10. Devroede G., Lemieux B., Masse S., Lamarche J., Herman P.S. Colonic hamartomas in tuberous sclerosis. Gastroenterology. 94:1988;182-188
11. Duan C., Liimatta M.B., Bottum O.L. Insulin-like growth factor (IGF)-I regulates IGF-binding protein-5 gene expression through the phosphatidylinositol 3-kinase, protein kinase B/Akt, and p70 S6 kinase signaling pathway. J. Biol. Chem. 274:1999;37147-37153
12. El-Hashemite N., Walker V., Zhang H., Kwiatkowski D.J. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res. 63:2003;5173-5177
13. Entius M.M., Keller J.J., Westerman A.M., van Rees B.P., van Velthuysen M.L., de Goeij A.F., Wilson J.H., Giardiello F.M., Offerhaus G.J. Molecular genetic alterations in hamartomatous polyps and carcinomas of patients with Peutz-Jeghers syndrome. J. Clin. Pathol. 54:2001;126-131
14. Fingar D.C., Blenis J. Target of rapamycin (TOR). An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression Oncogene. 23:2004;3151-3171
15. Fingar D.C., Salama S., Tsou C., Harlow E., Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 16:2002;1472-1487
16. Garami A., Zwartkruis F.J.T., Nobukuni T., Joaquin M., Roccio M., Stocker H., Kozma S.C., Hafen E., Bos J.L., Thomas G. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell. 11:2003;1457-1466
17. Gomez, M.R., Sampson, J.R., and Whittemore, V.H. (1999). Tuberous Sclerosis, 3rd ed. (New York: Oxford University Press).
18. Hardie D.G., Scott J.W., Pan D.A., Hudson E.R. Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett. 546:2003;113-120
19. Harris, T.E., and Lawrence, J.C., Jr. (2003). TOR signaling. Sci STKE 2003, re15.
20. Hawley S.A., Boudeau J., Reid J.L., Mustard K.J., Udd L., Makela T.P., Alessi D.R., Hardie D.G. Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2:2003;28
21. Hemminki A., Tomlinson I., Markie D., Jarvinen H., Sistonen P., Bjorkqvist A.M., Knuutila S., Salovaara R., Bodmer W., Shibata D., et al. Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis. Nat. Genet. 15:1997;87-90
22. Huang S., Shu L., Dilling M.B., Easton J., Harwood F.C., Ichijo H., Houghton P.J. Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1). Mol. Cell. 11:2003;1491-1501
23. Inoki K., Li Y., Zhu T., Wu J., Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4:2002;648-657
24. Inoki K., Zhu T., Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 115:2003;577-590
25. Jishage K., Nezu J., Kawase Y., Iwata T., Watanabe M., Miyoshi A., Ose A., Habu K., Kake T., Kamada N., et al. Role of Lkb1, the causative gene of Peutz-Jegher's syndrome, in embryogenesis and polyposis. Proc. Natl. Acad. Sci. USA. 99:2002;8903-8908
26. Jaeschke A., Hartkamp J., Saitoh M., Roworth W., Nobukuni T., Hodges A., Sampson J., Thomas G., Lamb R. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent. J. Cell Biol. 159:2002;217-224
27. Jorgensen S.B., Viollet B., Andreelli F., Frosig C., Birk J.B., Schjerling P., Vaulont S., Richter E.A., Wojtaszewski J.F. Knockout of the α2 but not α1 5′-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside but not contraction-induced glucose uptake in skeletal muscle. J. Biol. Chem. 279:2004;1070-1079
28. Kemp B.E., Stapleton D., Campbell D.J., Chen Z.P., Murthy S., Walter M., Gupta A., Adams J.J., Katsis F., van Denderen B., et al. AMP-activated protein kinase, super metabolic regulator. Biochem. Soc. Trans. 31:2003;162-168
29. Kenerson H.L., Aicher L.D., True L.D., Yeung R.S. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res. 62:2002;5645-5650
30. Kimura N., Tokunaga C., Dalal S., Richardson C., Yoshino K., Hara K., Kemp B.E., Witters L.A., Mimura O., Yonezawa K. A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway. Genes Cells. 8:2003;65-79
31. Kwiatkowski D.J., Zhang H., Bandura J.L., Heiberger K.M., Glogauer M., el-Hashemite N., Onda H. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in TSC1 null cells. Hum. Mol. Genet. 11:2002;525-534
32. Kwon C.H., Zhu X., Zhang J., Baker S.J. mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. Proc. Natl. Acad. Sci. USA. 100:2003;12923-12928
33. Lizcano J.M., Goransson O., Toth R., Deak M., Morrice N.A., Boudeau J., Hawley S.A., Udd L., Makela T.P., Hardie D.G., Alessi D.R. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J. 23:2004;833-843
34. Loewith R., Jacinto E., Wullschleger S., Lorberg A., Crespo J.L., Bonenfant D., Oppliger W., Jenoe P., Hall M.N. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell. 10:2002;457-468
35. Manning B.D., Cantley L.C. United at last. The tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling Biochem. Soc. Trans. 31:2003;573-578
36. Manning B.D., Tee A.R., Logsdon M.N., Blenis J., Cantley L.C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/Akt pathway. Mol. Cell. 10:2002;151-162
37. Martin S.G., St Johnston D. A role for Drosophila LKB1 in anterior-posterior axis formation and epithelial polarity. Nature. 421:2003;379-384
38. Miyoshi H., Nakau M., Ishikawa T.O., Seldin M.F., Oshima M., Taketo M.M. Gastrointestinal hamartomatous polyposis in Lkb1 heterozygous knockout mice. Cancer Res. 62:2002;2261-2266
39. Neshat M.S., Mellinghoff I.K., Tran C., Stiles B., Thomas G., Petersen R., Frost P., Gibbons J.J., Wu H., Sawyers C.L. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA. 98:2001;10314-10319
40. Onda H., Crino P.B., Zhang H., Murphey R.D., Rastelli L., Gould-Rothberg B.E., Kwiatkowski D.J. TSC2 null murine neuroepithelial cells are a model for human tuber giant cells, and show activation of an mTOR pathway. Mol. Cell. Neurosci. 21:2002;561-574
41. Ossipova O., Bardeesy N., DePinho R.A., Green J.B. LKB1 (XEEK1) regulates Wnt signalling in vertebrate development. Nat. Cell Biol. 5:2003;889-894
42. Podsypanina K., Lee R.T., Politis C., Hennessy I., Crane A., Puc J., Neshat M., Wang H., Yang L., Gibbons J., et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in PTEN+/- mice. Proc. Natl. Acad. Sci. USA. 98:2001;10320-10325
43. Rajasekhar V.K., Viale A., Socci N.D., Wiedmann M., Hu X., Holland E.C. Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol. Cell. 12:2003;889-901
44. Ramaswamy S., Nakamura N., Vazquez F., Batt D.B., Perera S., Roberts T.M., Sellers W.R. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc. Natl. Acad. Sci. USA. 96:1999;2110-2115
45. Rossi D.J., Ylikorkala A., Korsisaari N., Salovaara R., Luukko K., Launonen V., Henkemeyer M., Ristimaki A., Aaltonen L.A., Makela T.P. Induction of cyclooxygenase-2 in a mouse model of Peutz-Jeghers polyposis. Proc. Natl. Acad. Sci. USA. 99:2002;12327-12332
46. Sakamoto, K., Goransson, O., Hardie, D.G., and Alessi, D.R. (2004). Activity of LKB1 and AMPK-related kinases in skeletal muscle: effects of contraction, phenformin and AICAR. Am. J. Physiol. Endocrinol. Metab. Published online April 6, 2004.
47. Sanchez-Cespedes M., Parrella P., Esteller M., Nomoto S., Trink B., Engles J.M., Westra W.H., Herman J.G., Sidransky D. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res. 62:2002;3659-3662
48. Scott J.W., Hawley S.A., Green K.A., Anis M., Stewart G., Scullion G.A., Norman D.G., Hardie D.G. CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations. J. Clin. Invest. 113:2004;274-284
49. Shamji A.F., Nghiem P., Schreiber S.L. Integration of growth factor and nutrient signaling. Implications for cancer biology Mol. Cell. 12:2003;271-280
50. Shaw R.J., Kosmatka M., Bardeesy N., Hurley R.L., Witters L.A., DePinho R.A., Cantley L.C. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl. Acad. Sci. USA. 101:2004;3329-3335
51. Shi Y., Gera J., Hu L., Hsu J., Bookstein R., Li W., Lichtenstein A. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res. 62:2002;5027-5034
52. Stambolic V., Suzuki A., delaPompa J.L., Brothers G.M., Mirtsos C., Sasaki T., Ruland J., Penninger J.M., Sioderovski D.P., Mak T.W. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 95:1998;29-39
53. Stein S.C., Woods A., Jones N.A., Davison M.D., Carling D. The regulation of AMP-activated protein kinase by phosphorylation. Biochem. J. 345:2000;437-443
54. Sun H., Lesche R., Li D., Liliental J., Zhang H., Gao J., Gavrilova N., Mueller B., Liu X., Wu H. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3, 4, 5-triphosphate and Akt/protein kinase B signaling pathway. Proc. Natl. Acad. Sci. USA. 96:1999;6199-6204
55. Tiainen M., Ylikorkala A., Makela T.P. Growth suppression by Lkb1 is mediated by a G(1) cell cycle arrest. Proc. Natl. Acad. Sci. USA. 96:1999;9248-9251
56. Viollet B., Andreelli F., Jorgensen S.B., Perrin C., Geloen A., Flamez D., Mu J., Lenzner C., Baud O., Bennoun M., et al. The AMP-activated protein kinase .2 catalytic subunit controls whole-body insulin sensitivity. J. Clin. Invest. 111:2003;91-98
57. Wang Z.J., Ellis I., Zauber P., Iwama T., Marchese C., Talbot I., Xue W.H., Yan Z.Y., Tomlinson I. Allelic imbalance at the LKB1 (STK11) locus in tumours from patients with Peutz-Jeghers' syndrome provides evidence for a hamartoma-(adenoma)-carcinoma sequence. J. Pathol. 188:1999;9-13
58. Watts J.L., Morton D.G., Bestman J., Kemphues K.J. The C. elegans par-4 gene encodes a putative serine-threonine kinase required for establishing embryonic asymmetry. Development. 127:2000;1467-1475
59. Woods A., Johnstone S.R., Dickerson K., Leiper F.C., Fryer L.G., Neumann D., Schlattner U., Wallimann T., Carlson M., Carling D. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr. Biol. 13:2003;2004-2008
60. Ylikorkala A., Rossi D.J., Korsisaari N., Luukko K., Alitalo K., Henkemeyer M., Makela T.P. Vascular abnormalities and deregulation of VEGF in Lkb1-deficient mice. Science. 293:2001;1323-1326
61. Zhang H., Cicchetti G., Onda H., Koon H.B., Asrican K., Bajraszewski N., Vazquez F., Carpenter C.L., Kwiatkowski D.J. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J. Clin. Invest. 112:2003;1223-1233